Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community.
Circulation. 144: 74-84Packer M. Butler J. Zannad F. et al.Empagliflozin and major renal outcomes in heart failure.
N Engl J Med. 385: 1531-1533Heerspink H.J.L. Jongs N. Chertow G.M. et al.Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes Endocrinol. 9: 743-754McGuire D.K. Shih W.J. Cosentino F. et al.Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.
JAMA Cardiol. 6: 148-158Zinman B. Wanner C. Lachin J.M. et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
N Engl J Med. 373: 2117-2128Neal B. Perkovic V. Mahaffey K.W. et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes.
N Engl J Med. 377: 644-657Wiviott S.D. Raz I. Bonaca M.P. et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
N Engl J Med. 380: 347-357Perkovic V. Jardine M.J. Neal B. et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl J Med. 380: 2295-2306Cannon C.P. Pratley R. Dagogo-Jack S. et al.Cardiovascular outcomes with ertugliflozin in type 2 diabetes.
N Engl J Med. 383: 1425-1435Bhatt D.L. Szarek M. Pitt B. et al.Sotagliflozin in patients with diabetes and chronic kidney disease.
N Engl J Med. 384: 129-139Salah H.M. Al'Aref S.J. Khan M.S. et al.Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: a meta-analysis update.
Am Heart J. 233: 86-91Zheng S.L. Roddick A.J. Aghar-Jaffar R. et al.Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis.
JAMA. 319: 1580-1591Kohsaka S. Lam C.S.P. Kim D.J. et al.Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Lancet Diabetes Endocrinol. 8: 606-615Heerspink H.J.L. Stefansson B.V. Correa-Rotter R. et al.Dapagliflozin in patients with chronic kidney disease.
N Engl J Med. 383: 1436-1446Anker S.D. Butler J. Filippatos G. et al.Empagliflozin in heart failure with a preserved ejection fraction.
N Engl J Med. 385: 1451-1461McMurray J.J.V. Solomon S.D. Inzucchi S.E. et al.Dapagliflozin in patients with heart failure and reduced ejection fraction.
N Engl J Med. 381: 1995-2008Packer M. Anker S.D. Butler J. et al.Cardiovascular and renal outcomes with empagliflozin in heart failure.
N Engl J Med. 383: 1413-1424McMurray J.J.V. Wheeler D.C. Stefansson B.V. et al.Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease.
Circulation. 143: 438-448Storgaard H. Gluud L.L. Bennett C. et al.Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis.
PLoS One. 11: e0166125Sanchez-Garcia A. Simental-Mendia M. Millan-Alanis J.M. et al.Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials.
Pharmacol Res. 160: 105068Han J.H. Oh T.J. Lee G. et al.The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet.
Diabetologia. 60: 364-376Mancini S.J. Boyd D. Katwan O.J. et al.Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Sci Rep. 8: 5276Xu C. Wang W. Zhong J. et al.Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells.
Biochem Pharmacol. 152: 45-59Hess D.A. Terenzi D.C. Trac J.Z. et al.SGLT2 Inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus.
Cell Metab. 30: 609-613Nakatsu Y. Kokubo H. Bumdelger B. et al.The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mrna levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice.
Int J Mol Sci. 18Ganbaatar B. Fukuda D. Shinohara M. et al.Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
Eur J Pharmacol. 875: 173040Leng W. Ouyang X. Lei X. et al.The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-/-) mice.
Mediators Inflamm. 2016: 6305735Rahadian A. Fukuda D. Salim H.M. et al.Canagliflozin prevents diabetes-induced vascular dysfunction in apoe-deficient mice.
J Atheroscler Thromb. 27: 1141-1151Kim S.R. Lee S.G. Kim S.H. et al.SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
Nat Commun. 11: 2127Ye Y. Bajaj M. Yang H.C. et al.SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor.
Cardiovasc Drugs Ther. 31: 119-132Park S.H. Belcastro E. Hasan H. et al.Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
Cardiovasc Diabetol. 20: 65Spigoni V. Fantuzzi F. Carubbi C. et al.Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
Cardiovasc Diabetol. 19: 46Uthman L. Homayr A. Juni R.P. et al.Empagliflozin and dapagliflozin reduce ROS Generation and restore no bioavailability in tumor necrosis factor alpha-stimulated human coronary arterial endothelial cells.
Cell Physiol Biochem. 53: 865-886Oelze M. Kroller-Schon S. Welschof P. et al.The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
PLoS One. 9: e112394Steven S. Oelze M. Hanf A. et al.The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Redox Biol. 13: 370-385Nasiri-Ansari N. Dimitriadis G.K. Agrogiannis G. et al.Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
Cardiovasc Diabetol. 17: 106Sukhanov S. Higashi Y. Yoshida T. et al.The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion.
Cell Signal. 77: 109825Adingupu D.D. Gopel S.O. Gronros J. et al.SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(-/-) mice.
Cardiovasc Diabetol. 18: 16Lee D.M. Battson M.L. Jarrell D.K. et al.SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Cardiovasc Diabetol. 17: 62Irace C. Cutruzzola A. Parise M. et al.Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study.
Diab Vasc Dis Res. 17 ()Sawada T. Uzu K. Hashimoto N. et al.Empagliflozin's ameliorating effect on plasma triglycerides: association with endothelial function recovery in diabetic patients with coronary artery disease.
J Atheroscler Thromb. 27: 644-656Sposito A.C. Breder I. Soares A.A.S. et al.Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Cardiovasc Diabetol. 20: 74Solini A. Seghieri M. Giannini L. et al.The effects of dapagliflozin on systemic and renal vascular function display an epigenetic signature.
J Clin Endocrinol Metab. 104: 4253-4263Zainordin N.A. Hatta S. Mohamed Shah F.Z. et al.Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED).
J Endocr Soc. 4: bvz017Bosch A. Ott C. Jung S. et al.How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Cardiovasc Diabetol. 18: 44Cherney D.Z. Perkins B.A. Soleymanlou N. et al.The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
Cardiovasc Diabetol. 13: 28Chilton R. Tikkanen I. Cannon C.P. et al.Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
Diabetes Obes Metab. 17: 1180-1193Hong J.Y. Park K.Y. Kim J.D. et al.Effects of 6 months of dapagliflozin treatment on metabolic profile and endothelial cell dysfunction for obese type 2 diabetes mellitus patients without atherosclerotic cardiovascular disease.
J Obes Metab Syndr. 29: 215-221Ikonomidis I. Pavlidis G. Thymis J. et al.Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment.
J Am Heart Assoc. 9: e015716Terasaki M. Hiromura M. Mori Y. et al.Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice.
PLoS One. 10: e0143396Dimitriadis G.K. Nasiri-Ansari N. Agrogiannis G. et al.Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice.
Mol Cell Endocrinol. 494: 110487Liu Y. Xu J. Wu M. et al.Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
Lipids Health Dis. 20: 5Chen Y.C. Jandeleit-Dahm K. Peter K.Sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced atherosclerotic plaque instability.
J Am Heart Assoc. 11: e022761D'Onofrio N. Sardu C. Trotta M.C. et al.Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
Mol Metab. 54: 101337Sattar N. McLaren J. Kristensen S.L. et al.SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?.
Diabetologia. 59: 1333-1339Chiba Y. Yamada T. Tsukita S. et al.Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice.
PLoS One. 11: e0150756Elliott R.H. Matthews V.B. Rudnicka C. et al.Is it time to think about the sodium glucose co-transporter 2 sympathetically?.
Nephrology (Carlton). 21: 286-294Herat L.Y. Magno A.L. Rudnicka C. et al.SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection.
JACC Basic Transl Sci. 5: 169-179Ridker P.M. Everett B.M. Thuren T. et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease.
N Engl J Med. 377: 1119-1131Bhatt D.L. Steg P.G. Miller M. et al.Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
N Engl J Med. 380: 11-22Cannon C.P. Blazing M.A. Giugliano R.P. et al.Ezetimibe added to statin therapy after acute coronary syndromes.
N Engl J Med. 372: 2387-2397
留言 (0)